TREADWELL THERAPEUTICS
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.
TREADWELL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2020-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.treadwelltx.com
Total Employee:
11+
Status:
Active
Total Funding:
118 M USD
Technology used in webpage:
Euro Cloudflare Hosting Lorem Ipsum
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Chess Therapeutics, LLC
It is an oncology focused biotechnology company developing novel microtubule targeted drugs with distinct spectrum of anti-cancer activity.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Prescient Therapeutics
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-15 | TCRyption | TCRyption acquired by Treadwell Therapeutics | N/A |
Investors List
Alpha Win Capital
Alpha Win Capital investment in Series B - Treadwell Therapeutics
Prosperous Alliance Investments
Prosperous Alliance Investments investment in Series B - Treadwell Therapeutics
3W Fund Management
3W Fund Management investment in Series B - Treadwell Therapeutics
TIO Bioventures
TIO Bioventures investment in Series B - Treadwell Therapeutics
Sino Biopharmaceutical
Sino Biopharmaceutical investment in Series B - Treadwell Therapeutics
Adrian Cheng
Adrian Cheng investment in Series B - Treadwell Therapeutics
Fortune Ocean Growth Fund
Fortune Ocean Growth Fund investment in Series B - Treadwell Therapeutics
Key Employee Changes
Official Site Inspections
http://www.treadwelltx.com Semrush global rank: 7.88 M Semrush visits lastest month: 679
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Treadwell Therapeutics"
About | Treadwell Therapeutics
Apr 24, 2024 We believe one solution rests in pursuing scientific areas that remain underexplored and underappreciated. Forging new ground in healthcare requires venturing …See details»
Treadwell Therapeutics - Crunchbase Company Profile …
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's …See details»
Treadwell Therapeutics Announces The Closing of a $91 Million …
Nov 18, 2021 Lastly, the funding will allow Treadwell to continue to grow and operationalize the organization with world class talent and infrastructure. About Treadwell Therapeutics …See details»
Treadwell Announces Strategic Pipeline Prioritization and …
– Treadwell to focus on advancing first-in-class PLK4 inhibitor CFI-400945 in AML towards potential pivotal studies in 2025 – Approximately 30% reduction in workforce to extend cash …See details»
Treadwell Announces the Formation and Members of Scientific …
TORONTO & SAN FRANCISCO, February 14, 2024--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines …See details»
Treadwell - Overview, News & Similar companies | ZoomInfo.com
Feb 3, 2023 Treadwell has announced that Roger Sidhu has joined the organization as Chief Medical Officer. Previously, Sidhu served as Chief Medical Officer for Eterna Therapeutics. ...See details»
Treadwell Announces the Formation and Members of Scientific …
TORONTO & SAN FRANCISCO–(BUSINESS WIRE)–Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines …See details»
Treadwell Therapeutics Announces Fast Track Designation
Apr 26, 2022 For more information, please visit www.treadwelltx.com. ... SOURCE Treadwell Therapeutics. × Modal title. Organization Profile. Treadwell Therapeutics. Contact Cision. 866 …See details»
Treadwell Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Nov 4, 2024 For more information, please visit Contact [email protected]. Clinical Result ASH Cell Therapy Immunotherapy AACR. ... The statistics for drugs in the Pipeline is the current …See details»
Treadwell Therapeutics Announces Acquisition of …
Oct 15, 2021 Treadwell Therapeutics acquires TCRyption, Inc., a novel TCR-based cell therapy company, adding to its growing pipeline of first in class agents.See details»
Treadwell Therapeutics Announces The Closing of a $91 Million …
Nov 18, 2021 NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell "), a clinical-stage biotechnology company developing novel, cross …See details»
Treadwell Announces Strategic Pipeline Prioritization and …
Dec 6, 2023 – Treadwell to focus on advancing first-in-class PLK4 inhibitor CFI-400945 in AML towards potential pivotal studies in 2025– Approximately 30% red...See details»
Treadwell Therapeutics Announces Acquisition of TCRyption
Oct 15, 2021 For more information, please visit www.treadwelltx.com. About TIO Bioventures TIO Bioventures is a boutique venture creation firm focused on funding the advancement of …See details»
Treadwell Announces Strategic Pipeline Prioritization and …
Dec 7, 2023 TORONTO AND SAN FRANCISCO, Dec 5, 2023 — Treadwell Therapeutics, a clinical-stage biotechnology company developing novel first-in-class medicines for unmet …See details»
Treadwell Therapeutics Announces A Presentation at the 2021
NEW YORK, Nov. 12, 2021 /CNW/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a …See details»
Treadwell Therapeutics Announces The Closing of a $91 Million …
Nov 18, 2021 NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics Announces The Closing of a $91 Million Series B FinancingSee details»
Treadwell Expands Operations with New Local Footprint at …
Feb 10, 2021 Leading new oncology start-up establishes its research and development base at the Princess Margaret Cancer Research Tower. Toronto, February 10, 2021 — Following a …See details»
Treadwell Therapeutics Announces a Presentation at the 2021 SITC …
Nov 12, 2021 General inquiries: [email protected] Release Summary Treadwell Therapeutics Announces A Presentation at the 2021 SITC Meeting Featuring a Clinical …See details»
Treadwell Therapeutics Announces the Appointment of J.D.
Apr 19, 2022 “The opportunity to join an organization that brings together all of my past experiences alongside such amazing vision, leadership, and devotion to the patient is a dream …See details»